Keywords: Takeda, Astellas, Financial results year to March 29010
Two of Japan’s top drugmakers - Takeda and Astellas - expect profits decline as patent expiries bite
Article | 13 May 2010
Reporting full fiscal-year to March 31, 2010, financial results, leading Japanese pharmaceutical companies Takeda Pharmaceuticals and Astellas Pharma have both forecast a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
